- Predictive Oncology develops AI-solutions designed to assist clinicians in formulating personalized treatment plans for oncological patients
- Artificial Intelligence is being increasingly used to help understand and accurately predict how drug therapies can interact with specific patients
- POAI’s TumorGenesis subsidiary is also creating laboratory-grown tumors to help clinicians and researchers to better test therapies
Predictive Oncology (NASDAQ: POAI), a knowledge-driven precision medicine company that focuses on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery, is set to play a key role as the integration of AI technology within cancer care continues to improve the accuracy and speed of diagnosis, aid clinical decision-making and lead to better health outcomes. The National Cancer Institute (“NCI”) in the United States has separately revealed that it is increasingly looking to invest in supporting research and developing infrastructure centered around the usage of AI in developing oncological treatments (https://ibn.fm/BFD5m) – a niche where Predictive Oncology is increasingly building a dominant presence. In addition, the White House has announced $2 billion funding for public and private sector “AI hubs” designed to drive key advances in AI as well as other computational technologies (https://ibn.fm/kcgSH).
A primary goal of precision cancer medicine is the accurate prediction of optimal drug therapies based upon the personalized molecular profiles of patient tumors; ideally, such predictions are based upon well-established molecular cause-and-effect relationships that are disrupted in…
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
